

**ANTIMIGRAINE AGENTS,  
OTHER – CGRP INHIBITORS  
PRIOR AUTHORIZATION FORM**



**Keystone First**

**PERFORMRx**<sup>SM</sup>  
Next Generation Pharmacy Benefits

(form effective 1/1/20)

Fax to PerformRx<sup>SM</sup> at **1-215-937-5018**, or to speak to a representative call **1-800-588-6767**.

**PRIOR AUTHORIZATION REQUEST INFORMATION**

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request	# of pages:	Name of office contact:
Contact's phone number:	LTC facility contact/phone:	

**PATIENT INFORMATION**

Patient name:	Patient ID #:	DOB:
Street address:	Apt. #:	City/state/zip:

**PRESCRIBER INFORMATION**

Prescriber name:	Specialty:	
State license #:	NPI:	MA Provider ID#:
Street address:	Suite #:	City/state/zip:
Phone:	Fax:	

**PHARMACY INFORMATION (Prescriber to identify the pharmacy that is to dispense the medication):**

Deliver to: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Physician's Office <input type="checkbox"/> Patient's Preferred Pharmacy Name:	
Pharmacy Phone #:	Pharmacy Fax #:
<input type="checkbox"/> I acknowledge that the patient agrees with the pharmacy chosen for delivery of this medication.	

**CLINICAL INFORMATION**

Product requested (clinical prior auth required):		
<input type="checkbox"/> Aimovig 70 mg/ml autoinjector (1 autoinjector/package)	<input type="checkbox"/> Ajovy 225 mg/1.5 ml syringe	
<input type="checkbox"/> Aimovig 140 mg/ml autoinjector (1 autoinjector/package)	<input type="checkbox"/> Emgality 120 mg/ml pen	
<input type="checkbox"/> Aimovig 140 mg dose (2 x 70 mg autoinjectors/package)	<input type="checkbox"/> Emgality 120 mg/ml syringe	
<input type="checkbox"/> _____	<input type="checkbox"/> _____	
Dose/directions	Quantity:	Refills:
Diagnosis (submit documentation):	DX code (required):	
Is the medication being prescribed by, or in consultation with, a neurologist or headache specialist? <input type="checkbox"/> Yes <i>Submit documentation of consultation, if applicable.</i> <input type="checkbox"/> No		

**INITIAL REQUESTS**

1. Has the patient averaged 4 or more migraine days per month over the past 3 months? <input type="checkbox"/> Yes <input type="checkbox"/> No
2. Does the patient have a confirmed diagnosis of migraine (with or without aura) according to the current International Headache Society Classification of Headache Disorders? <input type="checkbox"/> Yes - <i>Submit documentation of diagnosis.</i> <input type="checkbox"/> No
3. Does the patient have a history of trial and failure, contraindication, or intolerance of medications from the following 3 drug classes used for the prevention of migraine? <input type="checkbox"/> anticonvulsants (e.g., divalproex, topiramate, valproic acid) <input type="checkbox"/> antidepressants (e.g., amitriptyline, venlafaxine) <input type="checkbox"/> beta blockers (e.g., metoprolol, propranolol, timolol) <input type="checkbox"/> Yes - List medications tried: <input type="checkbox"/> No
4. Will the patient be using botulinum toxin (e.g., Botox, Dysport, Myobloc, Xeomin) concomitantly with the requested medication? <input type="checkbox"/> Yes - <i>Submit documentation of consultation, if applicable.</i> <input type="checkbox"/> No
5. Request for a non-preferred agent: Has the patient tried and failed the preferred CGRP Inhibitor, Emgality? <input type="checkbox"/> Yes <input type="checkbox"/> No
6. Provide average number of migraine days and headache days per month:

**RENEWAL REQUESTS**

1. Since starting the requested medication, did the patient experience a reduction in the average number of headache or migraine days per month or decrease in severity and/or duration of headaches or migraines? <input type="checkbox"/> Yes - <i>Submit documentation of clinical response.</i> <input type="checkbox"/> No
--

**PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION**

Prescriber signature:	Date:
-----------------------	-------

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.